This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Specific properties of shRNA-mediated CCR5 downregulation that enhance the inhibition of HIV-1 infection in combination with shRNA targeting HIV-1 rev
Molecular Biology Reports Open Access 12 September 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lee, N.S. et al. Nat. Biotechnol. 20, 500–505 (2002).
Jacque, J.M., Triques, K. & Stevenson, M. Nature 418, 435–438 (2002).
Novina, C.D. et al. Nat. Med. 8, 681–686 (2002).
Gitlin, L., Karelsky, S. & Andino, R. Nature 418, 430–434 (2002).
Huang, Y. et al. Nat. Med. 2, 1240–1243 (1996).
Brummelkamp, T.R., Bernards, R. & Agami, R. Science 296, 550–553 (2002).
Martinez, M.A. et al. AIDS 16, 2385–2390 (2002).
Qin, X.-F., An, D.S., Chen, I.S.Y. & Baltimore, D. Proc. Natl. Acad. Sci. USA 100, 183–188 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arteaga, H., Hinkula, J., van Dijk-Härd, I. et al. Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol 21, 230–231 (2003). https://doi.org/10.1038/nbt0303-230
Issue Date:
DOI: https://doi.org/10.1038/nbt0303-230
This article is cited by
-
Specific properties of shRNA-mediated CCR5 downregulation that enhance the inhibition of HIV-1 infection in combination with shRNA targeting HIV-1 rev
Molecular Biology Reports (2022)
-
OuaSelect, a novel ouabain-resistant human marker gene that allows efficient cell selection within 48 h
Gene Therapy (2007)
-
Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA
Gene Therapy (2006)
-
siRNA therapeutics: big potential from small RNAs
Gene Therapy (2005)